Trail Ridge Investment Advisors LLC Invests $1.30 Million in United Therapeutics Corporation $UTHR

Key Points

• Trail Ridge Investment Advisors initiated a $1.30 million position in United Therapeutics by purchasing 2,400 shares during the second quarter. Institutional investors collectively own 94.08% of the company.
• United Therapeutics beat quarterly earnings expectations, reporting $7.27 in EPS versus the $6.86 consensus, although revenue fell 1.9% year over year to $783.3 million. Analysts maintain a “Moderate Buy” consensus with an average price target of $646, compared with the stock’s $512.88 opening price.
• Company insiders have been selling shares, including the CEO and an executive vice president; insiders sold 434,075 shares worth approximately $233.9 million over the past three months.

Trail Ridge Investment Advisors LLC bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,400 shares of the biotechnology company's stock, valued at approximately $1,300,000.

A number of other large investors also recently made changes to their positions in UTHR. Torren Management LLC acquired a new stake in United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after buying an additional 56 shares in the last quarter. Entrust Financial LLC bought a new position in United Therapeutics during the 4th quarter worth $31,000. International Assets Investment Management LLC increased its position in United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after buying an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Trading Down 0.0%

Shares of United Therapeutics stock opened at $512.88 on Tuesday. The firm's 50 day moving average is $532.35 and its 200 day moving average is $538.04. The firm has a market capitalization of $22.00 billion, a PE ratio of 18.35, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the business posted $6.41 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company's stock, valued at approximately $168,188,006.77. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 434,075 shares of company stock worth $233,942,595. 8.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on UTHR. Wells Fargo & Company upgraded shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Finally, Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $646.00.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source